Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Healthcare
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire May 22, 2023

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

GlobeNewswire April 26, 2023

PolyPid to Participate in Upcoming Investor Conferences

GlobeNewswire April 24, 2023

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

GlobeNewswire April 14, 2023

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

GlobeNewswire March 31, 2023

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

GlobeNewswire March 29, 2023

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire March 28, 2023

PolyPid to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 7, 2023

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 8, 2023

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

GlobeNewswire January 31, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

GlobeNewswire January 24, 2023

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire January 3, 2023

PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

GlobeNewswire December 12, 2022

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire December 9, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

GlobeNewswire November 29, 2022

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 9, 2022

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

GlobeNewswire October 26, 2022

PolyPid Announces Cost Reduction Plan

GlobeNewswire October 20, 2022

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire September 28, 2022